Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK2B | P67870 | 1/20 | 0.43 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.43 |
| ▸ | IDH1 | O75874 | 11/20 | 0.42 |
| ▸ | FAAH | O00519 | 1/20 | 0.41 |
| ▸ | NAAA | Q02083 | 1/20 | 0.41 |
| ▸ | PPARA | Q07869 | 1/20 | 0.38 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.37 |
| ▸ | MTOR | P42345 | 2/20 | 0.37 |
| ▸ | IL6ST | P40189 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2683643 | 1.00 | CSNK2B (0.43) | CSNK2BCSNK2A1IDH1FAAHNAAA | |
| SCHEMBL2683647 | 1.00 | CSNK2B (0.43) | CSNK2BCSNK2A1IDH1FAAHNAAA | |
| SCHEMBL4560345 | 1.00 | CSNK2B (0.43) | CSNK2BCSNK2A1IDH1FAAHNAAA | |
| SCHEMBL4560346 | 1.00 | CSNK2B (0.43) | CSNK2BCSNK2A1IDH1FAAHNAAA | |
| SCHEMBL16819921 | 0.81 | SIGMAR1 (0.42) | CSNK2BCSNK2A1NAAA | |
| SCHEMBL16819922 | 0.81 | SIGMAR1 (0.42) | CSNK2BCSNK2A1NAAA | |
| SCHEMBL18927361 | 0.81 | SIGMAR1 (0.42) | CSNK2BCSNK2A1NAAA | |
| SCHEMBL16819973 | 0.81 | SIGMAR1 (0.42) | CSNK2BCSNK2A1NAAA | |
| SCHEMBL18919020 | 0.81 | SIGMAR1 (0.42) | CSNK2BCSNK2A1NAAA | |
| SCHEMBL14645206 | 0.81 | NAAA (0.42) | CSNK2BCSNK2A1IDH1FAAHNAAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090270380-A1 | 3,4,5-Substituted Piperidines as Renin Inhibitors | NOVARTIS AG (CH) | 2009-10-29 | — | — | US | disclosed |
| EP-1863763-A1 | 3,4,5-SUBSTITUTED PIPERIDINES AS RENIN INHIBITORS | Speedel Experimenta AG (CH) | 2007-12-12 | — | — | EP | disclosed |
| EP-1816122-A2 | 3,4,5-substituted piperidines as therapeutic compounds | Speedel Experimenta AG (CH) | 2007-08-08 | — | — | EP | disclosed |
| US-20070167433-A1 | 3,4,5-Substituted piperidines as therapeutic compounds | SPEEDEL EXPERIMENTA AG (CH) | 2007-07-19 | — | — | US | disclosed |
| WO-2006103275-A1 | 3,4,5-SUBSTITUTED PIPERIDINES AS RENIN INHIBITORS | SPEEDEL EXPERIMENTA AG (CH) | 2006-10-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070167433-A1 | 3,4,5-Substituted piperidines as therapeutic compounds | CTSD, CTSL, CTSZ | CSNK2B 1961/4885CSNK2A1 2421/4885IDH1 2039/4885 |
| US-20090270380-A1 | 3,4,5-Substituted Piperidines as Renin Inhibitors | REN, AGTR1, AGTR2 | CSNK2B 2282/4885CSNK2A1 2294/4885IDH1 2140/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.